InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,985.38
(
0.02%
)
US TECH 100
20,490.00
(
0.00%
)
Dow Jones
43,958.19
(
0.11%
)
Brent Oil
72.13
(
0.36%
)
Bitcoin
90,914.62
(
0.39%
)
Post# of 253594
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120719
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rfj1862 post# 224231

Thursday, 03/21/2019 4:55:29 PM

Thursday, March 21, 2019 4:55:29 PM

Post# of 253594
I like ENTA’s chances in NASH for the reasons mentioned in #msg-146937904: a validated target and proven drug-discovery expertise in liver diseases.

Moreover, ENTA is an EPS-accretive buyout candidate right now for many companies, based on reasonable assumptions about cost synergies and tax rates.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up